The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II single-arm, multicenter, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple-negative breast cancer: Neoimmunoboost.
 
Peter A. Fasching
Honoraria - Amgen; AstraZeneca; BioNTech (Inst); Celgene; Cepheid (Inst); Daiichi Sankyo; Eisai; Hexal; Lilly; Merck Sharp & Dohme; Myelo Therapeutics GmbH; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Hexal; Macrogenics; Merck Sharp & Dohme; Myelo Therapeutics GmbH; Novartis; Pfizer; Puma Biotechnology; Roche; Teva
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst)
 
Andreas Hartkopf
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Eisai; Genomic Health; Lilly; MSD; Novartis; Pfizer; Roche; Teva
Speakers' Bureau - AstraZeneca; Clovis Oncology; Lilly; Novartis; Pfizer; Roche; Teva
Research Funding - Genomic Health (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche
 
Hans-Christian Kolberg
Stock and Other Ownership Interests - Phaon Scientific; Theraclion
Honoraria - Amgen; AstraZeneca; Carl Zeiss Meditec; Genomic Health; MSD Oncology; Novartis; Pfizer; Roche; SurgVision; Theraclion; Theramex
Consulting or Advisory Role - Amgen; SurgVision
Travel, Accommodations, Expenses - Amgen; Carl Zeiss Meditec; Daiichi Sankyo; Genomic Health; LIV Pharma; Novartis; Pfizer; Roche; Tesaro
 
Lothar Haeberle
No Relationships to Disclose
 
Sarah Wetzig
No Relationships to Disclose
 
Christine Mau
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Clovis Oncology
 
Tobias Engler
No Relationships to Disclose
 
Matthias Rübner
No Relationships to Disclose
 
Hanna Hübner
Employment - Institut fuer Frauengesundheit GmbH
 
Anna-Katharin Theuser
No Relationships to Disclose
 
Nadine Hummel
No Relationships to Disclose
 
Sabrina Uhrig
No Relationships to Disclose
 
Matthias W. Beckmann
Research Funding - AstraZeneca (Inst); Celgene (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst)
 
Alexander Hein
No Relationships to Disclose
 
Michael Untch
Honoraria - Art tempi (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); MSD Oncology (Inst); Mundipharma (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Lilly (Inst); MSD Oncology (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst)